Clinical Trials Directory
Clinical Trials match your criteria
-
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression + Endocrine Therapy in Premenopausal pt with pN0-1, ER-+/HER2--BC and an Oncotype Recurrence Score < Than or E= to 25
A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (OFSET)
-
Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer (STELLAR-303)
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer
-
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy
A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence
-
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
-
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects (FLAMINGO-01)
A Randomized, Multicenter, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR After Both Neoadjuvant and Postoperative Adjuvant Trastuzumab-Based Therapy (FLAMINGO-01)
-
Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab (ARTISTRY-7)
A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
-
Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer (FORTITUDE-102)
A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression (FORTITUDE-102)
-
Determination and Validation of Lung EpiCheck; a Multianalyte Assay for Lung Cancer Prediction
Determination and Validation of Lung EpiCheck; a Multianalyte Assay for Lung Cancer Prediction A Case-Control Study
-
Ph3 of immunotherapy Based Drug Combo w/wo Cytoreductive Nephrectomy for metastatic RCC
Phase III Trial of Immunotherapy-Based Combination Therapy with or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial)
Navigate Your Health
Find a Cancer Physician
Find a Cancer Physician
Meet our doctors who specialize in the full range of cancer care. Our team of experts has experience in a variety of specialty areas. Together, we provide comprehensive evaluation, diagnosis and treatment options.
Learn More
Patient Portal
Patient Portal
If you are a patient at Orlando Health Cancer Institute, our free online patient portal provides an easy and secure way to manage your health information. Reach us from any location at a time that’s convenient for you.
Learn More
Virtual Visit
Virtual Visit
Need to talk with a doctor, but don’t want to leave your home? Try our virtual visit (telehealth) option to connect with a physician from your phone, tablet or computer.
Learn More